Tumor cell surface determinants in host immunity against metastases.
The treatment of cancer through the action of natural host defense mechanisms has been the goal of basic research and medicine. Expanding our understanding of the structure and function of major histocompatibility antigens (MHC) and of their interaction with peptide antigens in T cell immunity, and integrating it with the emerging data on the nature of tumor rejection antigens, may advance our ability to manipulate the immunogenicity of tumors. Downregulation of MHC class I in murine tumors and human tumors and the manipulation of some experimental systems is described.